Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Completed 31Recruiting 17Terminated 7Not yet recruiting 7Unknown 5Active not recruiting 5Withdrawn 4Suspended 1No longer available 1

Sponsor Class

OTHER 3NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 2Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Breast Neoplasms 2Prostatic Neoplasms 1Neoplasm Metastasis 1Hereditary Sensory and Autonomic Neuropathies 1Colorectal Neoplasms 1Brain Neoplasms 1

Interventions

Cyclophosphamide 129Cisplatin 119Radiotherapy 115pembrolizumab 111Carboplatin 97Paclitaxel 96Gemcitabine 96Magnetic Resonance Spectroscopy 80Nivolumab 76Bevacizumab 76Fluorouracil 74Dexamethasone 73Radiosurgery 66Docetaxel 59Rituximab 58Leucovorin 57Oxaliplatin 55Capecitabine 55Biopsy 53Doxorubicin 52fludarabine 51Drug Therapy 45durvalumab 44Cytarabine 44Etoposide 42fludarabine phosphate 40Pemetrexed 40Radiation 39atezolizumab 36Surveys and Questionnaires 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Withdrawn × neratinib × Clear all
NCT04901299 2023-08-01

HER2-Signal

Massachusetts General Hospital

Phase 2 Withdrawn
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT04781374 2023-07-11

Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer

Beth Israel Deaconess Medical Center

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT04856475 2022-03-02

NeraBrain

Jules Bordet Institute

Phase 2 Withdrawn
BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT01960023 2021-10-27

Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer

NSABP Foundation Inc

Phase 1/2 Withdrawn
Gastrointestinal

Hereditary Sensory and Autonomic Neuropathies, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡